Bacterial and Plasmid Vectors Global Market Report 2021 Featuring Sigma-Aldrich, ATUM, QIAGEN, Promega, Thermo Fisher Scientific, GenScript Biotech, Takara Bio, IBA, Bio-Rad Labs, New England Biolabs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Bacterial and Plasmid Vectors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

The global bacterial & plasmid vectors market is expected to grow from $0.34 billion in 2020 to $0.39 billion in 2021 at a compound annual growth rate (CAGR) of 14.7%. The market is expected to reach $0.68 billion in 2025 at a CAGR of 15%.

Major players in the bacterial & plasmid vectors market are Sigma-Aldrich Inc., ATUM, QIAGEN, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories, and New England Biolabs.

The bacterial & plasmid vectors market consists of sales of bacterial & plasmid vectors and related services by entities (organizations, sole traders and partnerships) that develop bacterial and plasmid vectors for biotechnological applications. Bacterial vectors are DNA molecules that are the basic tool of genetic engineering is used to introduce foreign genetic material into a host to replicate and amplify the foreign DNA sequences as a recombinant molecule.

The vectors are used for introducing definite gene into the target cell and command the cell's mechanism for protein synthesis to produce the protein encoded by the gene. These are used for the production of protein in biotechnology applications.

The bacterial & plasmid vectors market covered in this report is segmented by host type into E.coli expression vectors, other bacterial expression vectors and by application into genetics, molecular biology, bioinformatics, others.

The high cost of gene therapy is expected to limit the growth of the bacterial & plasmid vectors market during the forecast period. Gene therapy utilizes genuine gene to prevent or treat diseases which utilizes bacteria or plasmids as vectors. The cost of gene therapy treatments approved by the Food and Drug Administration is between $0.3 million and $2.1 million.

Moreover, the cost of Luxturna gene therapy for certain inherited retinal diseases (IRDs) is $0.4 million per eye and LentiGlobin a gene therapy by Bluebird Bio designed to increase the levels of hemoglobin costs around $2.1 million. Stringent government regulations, long approval processes, and production costs are the major factors leading to the high cost of gene therapy. Thus, the high cost of gene therapy is to hinder the growth of the bacterial & plasmid vectors market in the near future.

Increasing the prevalence of cancer and infectious diseases is anticipated to boost the demand for bacterial & plasmid vectors market over the coming years. Bacteria are used as vectors for the delivery of recombinant proteins into target cells for the treatment of cancer and various infectious diseases. According to the World Health Organization (WHO), cancer is a second leading cause death worldwide, responsible for an estimated 9.6 million deaths in 2018.

Moreover, according to the WHO, the world is facing many public health threats which include various issues from climate change to inadequate healthcare facilities, wherein infectious diseases dominated WHO's list of 2019 health threats. Therefore, the growing prevalence of cancer and various infectious diseases and surging demand for bacterial & plasmid vectors for gene therapy is projected to propel the market revenues for bacterial & plasmid vectors' market.

The focus areas for many companies in the bacterial and plasmid vectors market has shifted to increasing mergers and acquisitions to acquire more production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities, or gain access to new markets.

Key Topics Covered:

1. Executive Summary

2. Bacterial & Plasmid Vectors Market Characteristics

3. Bacterial & Plasmid Vectors Market Trends and Strategies

4. Impact Of COVID-19 On Bacterial & Plasmid Vectors

5. Bacterial & Plasmid Vectors Market Size and Growth

5.1. Global Bacterial & Plasmid Vectors Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. Global Bacterial & Plasmid Vectors Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Bacterial & Plasmid Vectors Market Segmentation

6.1. Global Bacterial & Plasmid Vectors Market, Segmentation by Host Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• E.Coli Expression Vectors
• Other Bacterial Expression Vectors

6.2. Global Bacterial & Plasmid Vectors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Genetics
• Molecular biology
• Bioinformatics
• Others

6.3. Global Bacterial & Plasmid Vectors Market, Segmentation by End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Hospitals
• Homecare
• Specialty Clinics
• Others

7. Bacterial & Plasmid Vectors Market Regional and Country Analysis

7.1. Global Bacterial & Plasmid Vectors Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Bacterial & Plasmid Vectors Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

• Sigma-Aldrich Inc.
• ATUM
• QIAGEN
• Promega Corporation
• Thermo Fisher Scientific Inc.
• GenScript Biotech Corporation
• Takara Bio Inc.
• IBA GmbH
• Bio-Rad Laboratories
• New England Biolabs
• Agilent Technologies
• Life Technologies Corporation
• Clontech Laboratories Inc.
• DNA TwoPointO Inc.

For more information about this report visit https://www.researchandmarkets.com/r/35w16u

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900